HUTCHMED (China) Limited (HMDCF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
HUTCHMED (China) Limited (HMDCF) trades at $2.16 with AI Score 44/100 (Grade C). HUTCHMED (China) Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for cancer and immunological diseases. Market cap: $1.88B, Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for HMDCF: HMDCF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HMDCF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
HMDCF: the 3 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
HUTCHMED (China) Limited (HMDCF) Healthcare & Pipeline Overview
HUTCHMED (China) Limited, a biopharmaceutical company based in Hong Kong, specializes in oncology and immunology. With a market capitalization of $1.88B, the company develops targeted therapies and commercializes prescription drugs, positioning itself within the specialty and generic drug manufacturing sector.
What Is the Investment Thesis for HMDCF?
HUTCHMED (China) Limited presents a focused investment opportunity within the biopharmaceutical sector, driven by its specialization in oncology and immunology. The company's robust pipeline of drug candidates, particularly in late-stage development, offers potential for significant revenue growth upon successful commercialization. With a market capitalization of $1.88B and a profit margin of 77.5%, HUTCHMED demonstrates financial stability. Key value drivers include successful clinical trial outcomes, regulatory approvals, and market penetration of its innovative therapies. Ongoing catalysts include advancing drug candidates through clinical trials and expanding its commercial presence in key markets. Potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies.
Based on FMP financials and quantitative analysis
HMDCF Key Highlights
Market capitalization of $1.88B, reflecting investor confidence in HUTCHMED's pipeline and market strategy.
- Profit margin of 77.5%, indicating strong profitability in its commercial operations.
- Gross margin of 8.9%, reflecting the cost of goods sold relative to revenue.
- Beta of 0.51, suggesting lower volatility compared to the overall market.
- Specialization in oncology and immunology, positioning the company in high-growth therapeutic areas.
Who Are HMDCF's Competitors?
HMDCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| APNHF Aspen Pharmacare Holdings Limited | $8.90 | +0.00% | $3.95B | 50 |
| APNHY Aspen Pharmacare Holdings Limited | $8.80 | +0.00% | $3.91B | 50 |
| CHSYF China Medical System Holdings Limited | $1.57 | +0.00% | $3.80B | 53 |
| CURLF Curaleaf Holdings, Inc. | $9.60 | -2.34% | $2.54B | 53 |
| DMPHF Dermapharm Holding SE | $47.69 | +0.00% | $2.36B | 50 |
| ANIP ANI Pharmaceuticals, Inc. | $77.32 | -0.90% | $1.76B | 95 |
| AVDL Avadel Pharmaceuticals plc | $21.64 | +0.00% | $2.12B | 64 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HMDCF's Key Strengths?
Strong focus on oncology and immunology.
- Proprietary drug pipeline with innovative drug candidates.
- Established commercial presence in China.
- Experienced management team with expertise in drug development.
What Are HMDCF's Weaknesses?
Reliance on successful clinical trial outcomes.
- Dependence on regulatory approvals.
- Competition from larger pharmaceutical companies.
- Limited geographic diversification.
What Could Drive HMDCF Stock Higher?
Clinical trial results for key drug candidates in the oncology/immunology pipeline.
- Potential regulatory approvals for new drugs in major markets.
- Expansion of commercial operations in China and other key markets.
- Strategic partnerships with other pharmaceutical companies.
- Advancements in research and development of novel therapies.
What Are the Key Risks for HMDCF?
Rich valuation — a P/E of 47.2 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Clinical trial failures for drug candidates.
- Regulatory setbacks or delays in drug approvals.
- Competition from larger pharmaceutical companies.
- Dependence on key personnel and management team.
- Economic and political instability in key markets.
What Are the Growth Opportunities for HMDCF?
- Expansion into New Therapeutic Areas: HUTCHMED has the opportunity to leverage its research and development capabilities to expand into new therapeutic areas beyond oncology and immunology. This could include developing treatments for other chronic diseases or exploring novel drug modalities. The global market for chronic diseases is estimated to reach $12 trillion by 2028, offering a significant growth opportunity for the company. Timeline: 3-5 years.
- Geographic Expansion: HUTCHMED can expand its commercial presence into new geographic markets, particularly in Europe and North America. This would involve establishing partnerships with local distributors or building its own sales and marketing infrastructure. The global pharmaceutical market is expected to reach $1.5 trillion by 2026, providing ample opportunity for geographic expansion. Timeline: 2-4 years.
- Strategic Acquisitions: HUTCHMED can pursue strategic acquisitions of smaller biotechnology companies or drug candidates to expand its product pipeline and technological capabilities. This would allow the company to accelerate its growth and diversify its portfolio. The market for mergers and acquisitions in the biotechnology sector is expected to remain active in the coming years. Timeline: Ongoing.
- Development of Combination Therapies: HUTCHMED can focus on developing combination therapies that combine its existing drugs with other treatments to improve efficacy and patient outcomes. This would involve conducting clinical trials to evaluate the safety and efficacy of these combinations. The market for combination therapies is growing rapidly, driven by the increasing complexity of diseases and the need for personalized treatment approaches. Timeline: 2-5 years.
- Leveraging Artificial Intelligence: HUTCHMED can leverage artificial intelligence (AI) and machine learning (ML) technologies to accelerate drug discovery and development. This would involve using AI to identify promising drug targets, optimize clinical trial designs, and personalize treatment strategies. Timeline: Ongoing.
What Are HMDCF's Competitive Advantages?
- Proprietary drug pipeline with patented drug candidates.
- Specialized expertise in oncology and immunology.
- Established commercial infrastructure in China.
- Strong relationships with key opinion leaders and healthcare providers.
- Regulatory expertise in navigating the drug approval process.
What Does HMDCF Do?
HUTCHMED (China) Limited, established on December 18, 2000, is a holding company engaged in the research, development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. Headquartered in Hong Kong, the company operates primarily through two segments: Oncology/Immunology and Other Ventures. The Oncology/Immunology segment focuses on discovering, developing, and commercializing targeted therapies and immunotherapies for cancer and immunological diseases. This includes novel drug candidates designed to address unmet medical needs in these therapeutic areas. The Other Ventures segment encompasses the commercial businesses, including the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. This segment supports the company's broader portfolio and provides a revenue stream to fund ongoing research and development efforts. HUTCHMED's strategic focus is on building a portfolio of innovative oncology and immunology drugs for the global market, with a strong emphasis on China. The company's product pipeline includes several late-stage drug candidates, positioning it for potential growth in the coming years. HUTCHMED leverages its research and development capabilities and commercial infrastructure to bring innovative medicines to patients.
What Products and Services Does HMDCF Offer?
- Researches and develops pharmaceutical products.
- Manufactures pharmaceutical products.
- Sells pharmaceutical products.
- Focuses on oncology and immunology therapies.
- Develops targeted therapies for cancer and immunological diseases.
- Commercializes prescription drugs.
- Distributes healthcare products.
How Does HMDCF Make Money?
- Develops and patents novel drug candidates.
- Conducts clinical trials to evaluate the safety and efficacy of its drugs.
- Obtains regulatory approvals from agencies such as the FDA and EMA.
- Manufactures and commercializes its approved drugs.
- Generates revenue through sales of its pharmaceutical products.
What Industry Does HMDCF Operate In?
HUTCHMED (China) Limited operates within the specialty and generic drug manufacturing industry, a sector characterized by intense competition and rapid innovation. The global oncology market is expected to reach $350 billion by 2030, driven by an aging population and increasing cancer incidence. The company's focus on targeted therapies and immunotherapies aligns with the industry's shift towards personalized medicine. Competitors include companies such as APNHF, APNHY, CHSYF, CURLF, and DMPHF, each vying for market share in specific therapeutic areas. HUTCHMED's strategic focus on the Chinese market provides a competitive advantage, given its local expertise and established infrastructure.
Who Are HMDCF's Key Customers?
- Patients suffering from cancer and immunological diseases.
- Hospitals and clinics that prescribe and administer HUTCHMED's drugs.
- Pharmacies that dispense HUTCHMED's drugs.
- Healthcare providers who recommend HUTCHMED's products.
Company Profile
HUTCHMED (China) Limited operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Hong Kong, HK. The company is led by CEO Chig Fung Cheng. HMDCF has traded publicly since 2014.
How HUTCHMED (China) Limited Is Valued
HUTCHMED (China) Limited carries a market capitalization of $1.88B, placing it in the small-cap category. Relative to its peer group, HMDCF's quantitative score of 44/100 is roughly in line with the peer average of 51/100.
Key Financial Metrics
Return on equity for HUTCHMED (China) Limited stands at 37.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 26.1%, showing how much profit it generates from its asset base. HMDCF trades at a trailing price-to-earnings ratio of 47.18, above the Healthcare sector average of ~23x. Its free cash flow yield is -4.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.96 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.1%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
HUTCHMED (China) Limited's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 3.28 places it in the safe zone, indicating low near-term bankruptcy risk.
Forward Outlook
Wall Street analysts project HUTCHMED (China) Limited revenue of about $604.3M for fiscal 2026, with EPS near $0.04. The estimate reflects 22 contributing analysts.
HMDCF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, signaling that key stakeholders believe in its growth potential.
- Community sentiment has turned more positive as discussions around HUTCHMED's innovative drug pipeline gain traction, indicating optimism among retail investors.
- Analysts have highlighted the potential of HUTCHMED's partnerships in expanding its market reach, which could enhance revenue streams moving forward.
- The overall healthcare sector's resilience amid economic uncertainties has bolstered investor confidence in HUTCHMED's business model.
Bear Case
- Concerns over regulatory challenges in China have resurfaced, creating apprehension among investors regarding operational risks.
- Social sentiment has shown signs of volatility, with some community members expressing skepticism about the company's ability to deliver on its ambitious growth targets.
- Recent market developments indicate increased competition in the biopharmaceutical space, which could pressure HUTCHMED's market position and profitability.
- The lingering effects of geopolitical tensions may impact investor sentiment negatively, leading to cautious trading behavior around the stock.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
HMDCF Latest News
No recent news available for HMDCF.
HMDCF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HMDCF.
Price Targets
Wall Street price target analysis for HMDCF.
HMDCF MoonshotScore
What does this score mean?
The MoonshotScore rates HMDCF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Chig Fung Cheng
Unknown
Information on Chig Fung Cheng's background is not available in the provided data. Details regarding his career history, education, and previous roles are unknown. Further research would be needed to provide a comprehensive profile.
Track Record: Information on Chig Fung Cheng's track record is not available in the provided data. Key achievements, strategic decisions, and company milestones under his leadership are unknown. Further research would be needed to provide a comprehensive assessment.
HMDCF OTC Market Information
The OTC Other tier, where HMDCF trades, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial reporting, making it difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies do not have to meet minimum listing standards, such as minimum share price or market capitalization requirements. This lack of regulation and oversight increases the risk associated with investing in OTC Other stocks.
- OTC Tier: OTC Other
- Limited financial disclosure, making it difficult to assess the company's financial health.
- Low trading volume, leading to potential price volatility.
- Lack of regulatory oversight, increasing the risk of fraud or mismanagement.
- Potential for delisting or suspension of trading.
- Limited access to company information and management.
- Verify the company's registration and legal status.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volume and price fluctuations.
- Consult with a financial advisor before investing.
- Established business operations in the pharmaceutical industry.
- Focus on oncology and immunology, areas of significant medical need.
- Presence of a management team, though details are limited.
- Market capitalization of $1.88B, suggesting some investor interest.
- Operations in Hong Kong, a major financial center.
HMDCF Healthcare Stock FAQ
What does the AI Score mean for HMDCF?
HMDCF holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. HUTCHMED (China) Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for cancer and immunological diseases. The company …
What does HUTCHMED (China) Limited do?
HUTCHMED (China) Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies, particularly in oncology and immunology. The company operates through its Oncology/Immunology segment, which focuses on targeted therapies for cancer and immunological diseases. Additionally, it has an Other Ventures segment involved in the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products.
What are the main risks for HMDCF?
The main risks for HUTCHMED (China) Limited include the potential for clinical trial failures, which could significantly impact its drug development pipeline. Regulatory setbacks or delays in drug approvals also pose a risk, as they could delay or prevent the commercialization of its products. Competition from larger pharmaceutical companies with greater resources and established market presence is another significant risk.
What are the key factors to evaluate for HMDCF?
HUTCHMED (China) Limited (HMDCF) holds an AI score of 44/100 (low). P/E: 47.2x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does HMDCF data refresh on this page?
HMDCF's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven HMDCF's recent stock price performance?
HUTCHMED (China) Limited (HMDCF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong focus on oncology and immunology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HMDCF overvalued or undervalued right now?
HUTCHMED (China) Limited (HMDCF) trades at 47.2x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research HMDCF before investing?
Before investing in HUTCHMED (China) Limited (HMDCF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding HMDCF to a portfolio?
Key strength of HUTCHMED (China) Limited (HMDCF): Strong focus on oncology and immunology. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information on CEO background and track record is limited.
- Analyst consensus and valuation metrics are unavailable.
- OTC analysis is based on general characteristics of the OTC Other tier.